Mereo BioPharma
MREO
66 hedge funds and large institutions have $305M invested in Mereo BioPharma in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 10 closing their positions.
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
49% more capital invested
Capital invested by funds: $205M → $305M (+$99.6M)
42% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $810K
40% more funds holding
Funds holding: 47 → 66 (+19)
0.56% more ownership
Funds ownership: 13.13% → 13.69% (+0.56%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$21.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$15.9M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$12.8M |
| 5 |
Millennium Management
New York
|
+$8.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.93M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.62M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$4M |
| 4 |
TLP
Tri Locum Partners
New York
|
-$2.61M |
| 5 |
Holocene Advisors
New York
|
-$2.07M |
MREO Hedge Fund Activity: Q1 2021 in Review
66 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2021, worth a combined $305M — up 49% from $205M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MREO positions and 10 closed out — a net gain of 19 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $29.3M. The largest seller was Citadel Advisors, cutting an estimated $5.93M.
- 66 institutional investors held Mereo BioPharma (MREO) as of Q1 2021, up from 47 in Q4 2020.
- Funds reported $305M of Mereo BioPharma stock for Q1 2021, up 49% quarter-over-quarter.
- 29 funds opened new Mereo BioPharma positions in Q1 2021 and 10 closed out, a net change of +19 holders.
- The largest Mereo BioPharma buyer in Q1 2021 was Point72 Asset Management, an estimated $29.3M added.
- The largest Mereo BioPharma seller in Q1 2021 was Citadel Advisors, an estimated $5.93M sold.
Based on aggregated 13F filings for Q1 2021.